Dermatológia pre prax 4/2019
Inhibition of interleukin 23 – in the treatment of chronic plaque psoriasis
Interleukin 23 (IL-23) inhibition is novel therapeutic approach in the treatment of chronic plaque psoriasis. IL-23 is a key cytokine in the differentiation of Th17 lymphocytes and production of proinflammatory cytokines leading to the onset of psoriasis. Through its inhibition proinflammatory pathway IL-23/Th17 is inhibited, without influencing IL-12/Th1 pathway with minimal involvement in psoriasis pathogenesis. Pathway IL-23/Th17 is considered as key inflammatory pathway in pathogenesis of not only psoriasis, but also other immunologically mediated diseases.
Keywords: interleukin 23, psoriasis, guselkumab, risankizumab
